Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
Zhiqiang Wang, Zhao-Cong Zhang, Yuyang Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 46

Showing 26-50 of 46 citing articles:

Development and Evaluation of [11C]I-58: A Novel PET Radiotracer Targeting BRD4 BD2 for Advanced Epigenetic Imaging
Yanli Wang, Yongle Wang, Yulong Xu, et al.
ACS Omega (2024)
Open Access | Times Cited: 1
Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics
Yupiao Feng, Xinting Hu, Xin Wang
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 1
BRD4: an effective target for organ fibrosis
Qun Wei, Cailing Gan, Meng Sun, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 1
SVA Regulation of Transposable Element Clustered Transcription within the Major Histocompatibility Complex Genomic Class II Region of the Parkinson’s Progression Markers Initiative
Jerzy K. Kulski, Abigail L. Pfaff, Sulev Kõks
Genes (2024) Vol. 15, Iss. 9, pp. 1185-1185
Open Access | Times Cited: 1
The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma.
Adena Pepich, Conny Tümmler, Sara Ajamieh, et al.
Cancer Letters (2024) Vol. 605, pp. 217261-217261
Open Access | Times Cited: 1
BET Protein Inhibitor JQ1 Ameliorates Experimental Peritoneal Damage by Inhibition of Inflammation and Oxidative Stress
Vanessa Marchant, Flavia Trionfetti, Lucía Tejedor-Santamaria, et al.
Antioxidants (2023) Vol. 12, Iss. 12, pp. 2055-2055
Open Access | Times Cited: 2
mRNA display in cell lysates enables identification of cyclic peptides targeting the BRD3 extraterminal domain
Catherine A. Hurd, Jacob T. Bush, Andrew J. Powell, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
The Prognostic Role of BRD4 Expression in High-Grade Serous Ovarian Cancer
Αngeliki Andrikopoulou, Garyfalia Bletsa, Angeliki Rouvalis, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 1962-1962
Open Access
mRNA Display in Cell Lysates Enables Identification of Cyclic Peptides Targeting the BRD3 Extraterminal Domain
Catherine A. Hurd, Jacob T. Bush, Andrew J. Powell, et al.
Angewandte Chemie (2024) Vol. 136, Iss. 38
Open Access
Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
Gregory S. Parker, Julia I. Toth, Sarah Fish, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 10, pp. 1446-1458
Open Access
Coupling proximity biotinylation with genomic targeting to characterize locus-specific changes in chromatin environments
Pata-Eting Kougnassoukou Tchara, Jérémy Loehr, Jean‐Philippe Lambert
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
A Novel BD2-Selective Inhibitor of BRDs Mitigates ROS Production and OA Pathogenesis
Hyemi Lee, Jihye Choe, Min‐Hee Son, et al.
Antioxidants (2024) Vol. 13, Iss. 8, pp. 943-943
Open Access
Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers
Annamaria Salvati, Giorgio Giurato, Jessica Lamberti, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access
The tripartite motif-containing 24 is a multifunctional player in human cancer
Yuanbing Yao, Sheng Zhou, Yan Yue, et al.
Cell & Bioscience (2024) Vol. 14, Iss. 1
Open Access
Bromodomain inhibitor treatment leads to overexpression of multiple kinases in cancer cells
Darshan S. Chandrashekar, Farrukh Afaq, Santhosh Kumar Karthikeyan, et al.
Neoplasia (2024) Vol. 57, pp. 101046-101046
Closed Access
Analysis of Modular Hub Genes and Therapeutic Targets across Stages of Non-Small Cell Lung Cancer Transcriptome
Angeli Joy B. Barretto, Marco A. Orda, Po‐Wei Tsai, et al.
Genes (2024) Vol. 15, Iss. 10, pp. 1248-1248
Open Access
Cancer Epigenetics and Bioinformatics
Tikam Chand Dakal, Abhijit Beura, Amandeep Kaur, et al.
Elsevier eBooks (2024)
Closed Access
BRD4 Degradation Enhanced Glioma Sensitivity to Temozolomide by Regulating Notch1 via Glu‐Modified GSH‐Responsive Nanoparticles
Linbin Yi, Zhenyu Zhang, Wenjie Zhou, et al.
Advanced Science (2024)
Open Access
Exploring the landscape of post-translational modification in drug discovery
Yuhao Cao, Tianyi Yu, Zhiguang Zhu, et al.
Pharmacology & Therapeutics (2024) Vol. 265, pp. 108749-108749
Closed Access
Emergent properties of the lysine methylome reveal regulatory roles via protein interactions and histone mimicry
Gareth Pollin, Young‐In Chi, Angela Mathison, et al.
Epigenomics (2024), pp. 1-16
Open Access
Epigenetic regulation of vascular smooth muscle cell phenotypes in atherosclerosis
Jordi Lambert, Helle F. Jørgensen
Atherosclerosis (2024), pp. 119085-119085
Open Access
New Quinazolynyl-Flavone Derivatives: Synthesis, Structure Analysis, and Investigation of Bromodomain Inhibitory Activities
Oya Bozdağ‐Dündar, Filiz Bakar‐Ates
Journal of Molecular Structure (2024), pp. 141267-141267
Closed Access
Discovery of a Natural Ent-Kaurene Diterpenoid Oridonin as an E3 Ligase Recruiter for PROTACs
Jie Huang, Xuekun Fu, Fang Qiu, et al.
Journal of the American Chemical Society (2024)
Closed Access
Previous Page - Page 2

Scroll to top